Skip to main content

Advertisement

Fig. 4 | Virology Journal

Fig. 4

From: Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation

Fig. 4

Percentages of HLA-A*0201/EBV-BMLF1-GLC- and HLA-A*1101/EBV-LMP2-SSC-specific CD8+ T cells in patients after haplo-HSCT. Data are expressed as the means ± standard deviations. The percentages of HLA-A*1101/LMP2-SSC-specific CTLs and HLA-A*0201/EBV-BMLF1-GLC-specific CTLs in EBV-seropositive healthy controls and in patients at + 30, + 60, and + 90 days after haplo-HSCT are shown. The percentages of HLA-A*1101/LMP2-SSC-specific CTLs and HLA-A*0201/EBV-BMLF1-GLC-specific CTLs in healthy controls were detected at only one-time point. The percentages of HLA-A*1101/LMP2-SSC-specific CTLs in healthy controls were 2.508% ± 1.766%, and the percentages of HLA-A*0201/EBV-BMLF1-GLC-specific CTLs in healthy controls were 2.222% ± 1.665%

Back to article page